miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression

Nahyun Choi; Jongmin Park; Jeon-Soo Lee; Jeehyun Yoe; Guk Yeol Park; Eunjeong Kim; Hyeongrin Jeon; Yong Mee Cho; Tae-Young Roh; Yoontae Lee

doi:10.18632/oncotarget.4372

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression

Nahyun Choi, Jongmin Park, Jeon-Soo Lee, Jeehyun Yoe, Guk Yeol Park, Eunjeong Kim, Hyeongrin Jeon, Yong Mee Cho, Tae-Young Roh and Yoontae Lee _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:23533-23547. https://doi.org/10.18632/oncotarget.4372

Metrics: PDF 2576 views | HTML 3932 views | ?

Abstract

Nahyun Choi1, Jongmin Park1, Jeon-Soo Lee1, Jeehyun Yoe1, Guk Yeol Park1, Eunjeong Kim1, Hyeongrin Jeon2, Yong Mee Cho3, Tae-Young Roh1,2 and Yoontae Lee1,2

1 Department of Life Sciences, Pohang University of Science and Technology, Pohang, Kyungbuk, Republic of Korea

2 Division of Integrative Bioscience and Biotechnology, Pohang University of Science and Technology, Pohang, Kyungbuk, Republic of Korea

3 Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea

Correspondence to:

Yoontae Lee, email:

Keywords: prostate cancer, capicua, ETV5, CRABP1, microRNA

Received: March 30, 2015 Accepted: May 30, 2015 Published: June 08, 2015

Abstract

Capicua (CIC) has been implicated in pathogenesis of spinocerebellar ataxia type-1 (SCA1) neurodegenerative disease and some types of cancer; however, the role of CIC in prostate cancer remains unknown. Here we show that CIC suppresses prostate cancer progression. CIC expression was markedly decreased in human prostatic carcinoma. CIC overexpression suppressed prostate cancer cell proliferation, invasion, and migration, whereas CIC RNAi exerted opposite effects. We found that knock-down of CIC derepresses expression of ETV5 and CRABP1 in LNCaP and PC-3 cells, respectively, thereby promoting cell proliferation and invasion. We also discovered that miR-93, miR-106b, and miR-375, which are known to be frequently overexpressed in prostate cancer patients, cooperatively down-regulate CIC levels to promote cancer progression. Altogether, we suggest miR-93/miR-106b/miR-375-CIC-CRABP1 as a novel key regulatory axis in prostate cancer progression.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4372

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression

Abstract